Key result
Nebivolol cuts adverse events ~48% vs second-generation beta-blockers with similar SBP reduction.
Why the study?
The comparative efficacy and safety of nebivolol versus other second-generation β blockers in hypertensive patients required evaluation.
Does nebivolol improve blood pressure reduction and safety compared with second-generation beta-blockers in patients with hypertension?
Meta-Analysis (n=1,154)
Does nebivolol improve blood pressure reduction and safety compared with second-generation beta-blockers in patients with hypertension?
Nebivolol provides comparable blood pressure lowering to second-generation beta-blockers in hypertensive patients while offering superior tolerability with nearly half the risk of adverse events and less heart rate reduction.
Answers are grounded in this paper and cite their sources.
Nebivolol matches second-generation beta-blockers for SBP reduction with half the adverse events; supports preferential use for tolerability in hypertension.
PURPOSE: Our meta-analysis was undertaken to evaluate the efficacy and safety of nebivolol compared with other second-generation β blockers for hypertensive patients. METHODS: We searched PubMed, the Cochrane Library, EMBASE, and Clinical Trials.gov databases for randomized controlled trials (RCTs). The efficacy endpoints included systolic blood pressure (SBP), diastolic blood pressure (DBP), reduction of SBP and DBP, heart rate (HR), and adverse events (AEs). FINDINGS: Eight RCTs with 1514 patients met the inclusion criteria. HR was significantly lower in patients receiving other second-generation β blockers compared with patients receiving nebivolol. There was no difference the reduction of blood pressure (SBP and DBP) or the reduction of SBP or DBP between the groups. The incidence of AEs was lower in patients taking nebivolol compared with patients taking other second-generation β blockers. CONCLUSIONS: No significant difference was demonstrated between nebivolol and other second-generation β blockers in the reduction of blood pressure, SBP, and DBP. The tolerability of nebivolol was significantly better compared with other second-generation β blockers, and nebivolol was also associated with a stable HR and a lower risk of AEs compared with other second-generation β blockers.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2020) conducted a meta-analysis in Hypertension (n=1,154). Nebivolol vs. Second-generation beta-blockers (atenolol 5-100 mg/day, bisoprolol 5 mg/day, metoprolol 50-100 mg/day) was evaluated on Reduction of systolic blood pressure (SBP) at 12 weeks (WMD 0.54, 95% CI -1.23 to 2.31). Nebivolol showed no significant difference in SBP reduction vs second-generation beta-blockers, but reduced adverse events.
Synapse has enriched 10 related papers. Consider them for comparative context: